פלאג'יל 250 מג טבליות Israel - Hebräisch - Ministry of Health

פלאג'יל 250 מג טבליות

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

לקסיבה Israel - Hebräisch - Ministry of Health

לקסיבה

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

לקסיבה Israel - Hebräisch - Ministry of Health

לקסיבה

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

רטרוביר לאינפוזיה תוך ורידית Israel - Hebräisch - Ministry of Health

רטרוביר לאינפוזיה תוך ורידית

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

נבלבין 20 מג Israel - Hebräisch - Ministry of Health

נבלבין 20 מג

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

ביקאלוטמיד אינובמד 150 מג Israel - Hebräisch - Ministry of Health

ביקאלוטמיד אינובמד 150 מג

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

ארומזין Israel - Hebräisch - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

סנדאימון   ניאורל   50 מג כמוסות Israel - Hebräisch - Ministry of Health

סנדאימון ניאורל 50 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

סנדאימון   ניאורל   100 מג כמוסות Israel - Hebräisch - Ministry of Health

סנדאימון ניאורל 100 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

פרוטופיק % 0.03 Israel - Hebräisch - Ministry of Health

פרוטופיק % 0.03

dexcel ltd, israel - tacrolimus - משחה - tacrolimus 0.03 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).